KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Assets Average (2016 - 2025)

Historic Assets Average for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $546.9 million.

  • Travere Therapeutics' Assets Average rose 363.41% to $546.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.9 million, marking a year-over-year increase of 363.41%. This contributed to the annual value of $691.5 million for FY2024, which is 536.85% down from last year.
  • Per Travere Therapeutics' latest filing, its Assets Average stood at $546.9 million for Q3 2025, which was up 363.41% from $552.1 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Assets Average peaked at $810.9 million during Q4 2023, and registered a low of $527.8 million during Q3 2024.
  • Over the past 5 years, Travere Therapeutics' median Assets Average value was $740.4 million (recorded in 2023), while the average stood at $696.1 million.
  • As far as peak fluctuations go, Travere Therapeutics' Assets Average surged by 2069.52% in 2021, and later tumbled by 3273.78% in 2024.
  • Travere Therapeutics' Assets Average (Quarter) stood at $775.9 million in 2021, then fell by 9.85% to $699.4 million in 2022, then rose by 15.94% to $810.9 million in 2023, then crashed by 32.26% to $549.3 million in 2024, then dropped by 0.42% to $546.9 million in 2025.
  • Its Assets Average was $546.9 million in Q3 2025, compared to $552.1 million in Q2 2025 and $571.5 million in Q1 2025.